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Abstract 
Purpose of review: To review novel therapeutic targets that are currently under 
investigation to develop safer, targeted therapies for antiphsopholipid antibody 
(aPL)-mediated clinical manifestations.  
Recent findings: Novel therapeutic options potentially available include anti-
CD20 monoclonal antibodies and new-generation anticoagulants (such as direct 
thrombin and anti-Xa inhibitors). Research focusing on interfering with aPL-
mediated cell activation, targeting complement components and the innovative 
concept of blocking the pathogenic sub-population of aPL with tailored peptides 
are currently being explored.  
Summary: Antiphospholipid syndrome is an autoimmune disease characterised 
by thrombosis and pregnancy morbidity occurring in patients persistently 
positive for aPL. Current therapeutic options remain confined to long-term 
anticoagulation with vitamin K antagonists. The future holds much promise with 
the identification of novel potential targets, many of which are currently under 
investigation. The challenge will be to design prospective randomized controlled 
clinical trials to provide the evidence necessary to support integration of these 
therapies into clinical practice. 
Keywords: antiphospholipid antibodies, antiphospholipid syndrome, novel 
therapy, thrombosis, pregnancy loss 
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Introduction  
The antiphospholipid syndrome (APS) is an autoimmune systemic disease 
characterised by vascular thrombosis and/or pregnancy morbidity occurring in 
patients persistently tested positive for antiphospholipid antibodies (aPL) [1]. 
Currently the only proven therapeutic option is long-term anticoagulation with 
vitamin K antagonists [2]. Indeed, management of APS centres on attenuating 
the procoagulant state whilst balancing the risks of anticoagulant therapy. 
However, despite the extensive use of long-term anticoagulation in the 
prevention and management of APS, there are ongoing concerns about efficacy 
and safety, including the narrow therapeutic window and numerous drug and 
dietary interactions. Adherence to treatment and the impact of long-term 
anticoagulation on daily life present many challenges for patients with APS, not 
least of which include so called ‘non-criteria’ manifestations such as cognitive 
dysfunction and fatigue [3]. Dietary interactions and regular, often frequent 
monitoring of the INR, which is inconvenient and costly, but essential to 
maintain the INR within the target therapeutic range are the most frequently 
reported patient concerns.  Moreover monitoring anticoagulation with vitamin K 
antagonists in patients with APS can be a real challenge, as the responsiveness 
of reagents used in the INR test in lupus anticoagulant positive patients vary 
widely, potentially leading to instability of anticoagulation [4]. Possibly because 
of these difficulties, recurrent thromboses and obstetric complications occur 
despite apparently optimum therapy. There is no consensus among experts on 
the best management or alternative options in such difficult cases. 
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There is therefore a major unmet need for novel therapies that ideally can avoid 
the need for regular INR testing but at the same time provide assurance that 
APS patients will be protected from further events. The use of novel 
anticoagulants in APS patients with venous thrombosis is being evaluated and 
until the trial data is available, patients are remaining on standard Vitamin K 
antagonists such as warfarin. Recent progress in understanding the pathogenic 
mechanisms of APS have opened new horizons for targeted therapies. Anti-
inflammatory and immunomodulatory pathways are currently being explored 
and represent promising approaches [5,6]. 
In this manuscript, we review novel therapeutic targets that are under 
investigation for the treatment of APS.  
 
New oral anticoagulants  
The new oral anticoagulants include dabigatran etexilate (Pradaxa®), a direct 
thrombin inhibitor, rivaroxaban (Xarelto®), apixaban (Eliquis) and edoxaban 
(Lixiana®), which are direct anti-Xa inhibitors. These emerging agents represent 
a major advance as, unlike the vitamin K antagonists, they have few reported 
drug interactions that could affect anticoagulant intensity and they seem not to 
interact with dietary foods [4, 7, 8]. All these agents have very predictable 
anticoagulant effects with fixed dosing regiments, making it unnecessary to 
routinely monitor anticoagulant intensity. Whilst this is very appealing from a 
patient perspective, one of the advantages of traditional vitamin K antagonists is 
that measuring and recording the INR ensures adherence to therapy. The lack 
of INR monitoring with the novel agents may introduce variability in patient 
adherence to therapy which could be hard to detect, an issue which is generally 
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under recognised with any oral therapy. APS patients are unique in that, 
anecdotally, many patients have a sense of their INR and feel unwell when it is 
below the target range, something that does not occur in other thrombotic 
disorders. It remains to be seen whether patients report similar symptoms with 
these novel agents.  
The efficacy of the novel anticoagulants has been demonstrated in large phase 
III clinical trials [9, 10], and both rivaroxaban and dabigatran have been licensed 
by the European Medicines Agency for the prevention of stroke and systemic 
embolism in patients with atrial fibrillation [11, 12]. In a randomized, double-
blind, non-inferiority trial involving patients with acute venous thromboembolism 
a fixed dose of oral dabigatran was found as effective and safe as warfarin, with 
the advantage of not requiring laboratory monitoring[13]. Rivaroxaban was 
superior to vitamin K antagonists in preventing a recurrent thrombotic event 
following 12 months post primary event warfarin administration [14]. These 
studies demonstrated low incidences of major bleeding, with dabigatran being 
at least similar if not superior to warfarin. These new agents would be expected 
to improve the quality of life in APS patients. However, in order to assess 
whether these new agents are as effective as warfarin in APS patients, we are 
currently conducting the RAPS (Rivaroxaban in AntiPhospholipid Syndrome, 
IRSCTN 68222801) trial. RAPS is a prospective randomised controlled trial of 
warfarin versus rivaroxaban in patients with venous thrombotic APS, with or 
without SLE, being maintained at a target INR of 2.5 (i.e. range 2.0–3.0)[15]. 
Hydroxychloroquine (HCQ) has been proposed to reduce the risk of thrombosis 
in clinical studies and animal models of APS [16, 17]. Its potential antithrombotic 
mechanisms include inhibition of platelet aggregation and adhesion [18], 
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cholesterol-lowering mechanisms [18] and blockade of aPL production [19]. 
Raden and co-workers showed that HCQ significantly reduced the binding of 
aPL-beta2GPI complexes to phospholipid surfaces. The drug also reduced the 
binding of the individual proteins to bilayers. The same study observed that 
HCQ also caused modest, but statistically significant, reductions of clinical 
antiphospholipid antibody titers [20]. HCQ was also found to reduce the 
disruption by aPL of the annexin A5 anticoagulant shield [21]. A beneficial effect 
of HCQ on primary thrombosis prevention in aPL positive patients was shown in 
both retrospective and prospective studies [22, 23]. Kaieser and co-workers 
confirmed, in a large and ethnically diverse SLE cohort including 1930 patients, 
that HCQ use was protective for thrombosis [23].  
Recently, Albert and co-workers showed that HCQ reversed the aPL-inhibition 
of trophoblast IL-6 secretion and partially limited aPL-inhibition of cell migration, 
suggesting that some form of combination therapy that includes HCQ may be 
beneficial to pregnant APS patients. A randomized multicenter study has been 
initiated to address the prophylactic role of HCQ against thrombosis in patients 
with aPL [24]. 
Statins are a class of drugs used to lower cholesterol levels by inhibiting the 
enzyme HMG-CoA reductase. They have been shown to have additional anti-
inflammatory, immunoregulatory and anti-thrombotic effects in vitro and in vivo 
[25, 26]. Their efficacy in primary and secondary prevention of cardiovascular 
events [27, 28] and venous thrombosis [29] has been demonstrated in the 
general population. Statins have been shown to decrease aPL-induced 
endothelial cell activation via inhibition of the expression of adhesion molecules 
and IL-6 and by reversal of tissue factor (TF) upregulation [30-33]. Statins also 
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have a variety of direct effects on gene expression and on the function of cells 
of both the innate and adaptive immune systems [34].  By altering 
isoprenylation, which in turn induces the inhibition of the small GTP-binding 
proteins Rho, Ras, and Rac, statins are able to decrease oxidative stress and 
inflammation, inhibit the thrombogenic response, and exert beneficial effects on 
the immune system [35]. In APS, statins have been demonstrated to interfere 
with monocyte, lymphocyte, and endothelial cell function, all of which may 
contribute to thrombosis prevention in aPL positive patients [31, 36, 37]. 
Preliminary results of an ongoing Phase 2 clinical trial investigating the levels of 
proinflammatory/prothrombotic biomarkers in aPL patients, reported a 
significant decrease in vascular endothelial growth factor, soluble TF and TNF 
titres after 30 day’s therapy with fluvastatin (40mg/daily) [38, 39]. Randomized 
controlled trials are needed to confirm these promising preliminary results 
supporting the effectiveness of statins in the prevention of thrombosis in aPL-
positive patients. The major difficulty with primary prevention trials of this nature 
is the very large sample size needed to provide a definitive answer, and this is 
challenging in a condition like APS. In vitro evidence for the use of pravastatin 
in pregnancy are still not conclusive and its role in preventing pregnancy 
complications in patients positive for aPL is still debated [40]. The in vivo 
condition may be more complex, and the effectiveness of pravastatin in the 
prevention of aPL-associated pregnancy complications in humans remains 
under investigation. 
Rituximab (RTX), is an anti-CD20 monoclonal antibody that induces rapid and 
almost complete depletion of CD20+ B cell populations. Originally approved for 
the treatment of B cell lymphomas,  RTX has successfully been used in the 
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treatment of systemic autoimmune diseases, including systemic lupus 
erythematosus (SLE), ANCA associated vasculitis and rheumatoid arthritis. In 
contrast to rheumatoid arthritis and ANCA vasculitis however, two large 
randomised controlled trials of RTX failed to meet their primary end-points in 
SLE. Despite these results, RTX continues to be widely used ‘off-label’ for 
treatment resistant SLE. RTX use has also been reported in APS, mainly in 
severe cases with thrombocytopenia or autoimmune haemolytic anemia [41] 
and in  APS patients resistant to standard therapy [42, 43]. Erre and co-workers 
described 12 patients with primary and SLE-associated APS who were treated 
with RTX [42]. RTX has also been shown to be an effective therapeutic option 
for life-threatening Catastrophic APS in a small number of patients [44]. B cells 
are likely to play a central role in the generation of the aPL-induced clinical 
manifestations of the disease, so could constitute a therapeutic target in APS. 
Anecdotally, its use has also been associated with a downregulation of aPL 
titers [45] and with a reduced rate of recurrent thrombosis in APS patients 
followed for 10–36 months post-RTX [43].  
Very recently, a pilot open-label phase II trial of RTX for non-criteria 
manifestations of APS (such as thrombocytopenia, skin ulcers, nephropathy, 
and cognitive dysfunction) concluded that RTX may represent a safe option in 
the therapeutic arsenal for APS, However, it has been reported to be effective in 
controlling some but not all non-criteria manifestations of APS [46].  
TF inhibition. The upregulation of TF in both immune cells, especially 
monocytes and the vascular endothelium seems to play a key role in the 
pathogenetic mechanism for aPL-induced thrombosis [47]. Inhibition of TF and 
associated pathways by which aPL induce TF expression may represent  
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potential therapeutic targets in APS. Currently, some agents have been 
suggested to induce in vitro TF inhibition.  These include ACE inhibitors, 
pentoxifylline, an adenosine uptake inhibitor (dilazep), and ss-deoxyribonucleic 
acid derivatives (e.g, defibrotide) [48]. Novel pharmacologic strategies aiming to 
inhibit TF upregualtion have also been developed, mainly in cardiovascular 
disease. Several potential mechanisms have been targeted, including TF 
synthesis inhibition, TF blockade using anti-TF antibodies, or recombinant TF 
pathway inhibitors [49]. In an open-label trial in patients with stable coronary 
artery disease, Sunol-cH36, a chimeric monoclonal anti–TF antibody exhibited  
dose-dependent anticoagulant effects inhibiting thrombin formation [50]. The 
clinical applications of such strategies in APS need to be tested in well-
designed clinical trials. 
Nuclear factor-kB and P38 mitogen-activated kinase inhibitors: The nuclear 
factor-kB (NF-kB) and the p38 MAPK pathways are the major intracellular 
mechanisms involved in the aPL-induced activation of platelets, endothelial 
cells and monocytes. In vitro, NF-KB inhibition was associated with a reduction 
of proinflammatory/prothrombotic biomarkers, including chemokines (CX3CL1 
and CCL5) and cytokines (IL-1 and TNFα) [51].  In vitro reduction of expression 
of TF was also observed when blocking NF-KB [51]. SB 203580 is an inhibitor 
of p38α and p38β which suppresses downstream activation of MAPKAP kinase-
2 and heat shock protein 27. It has been shown to act at low concentration as a 
specific p38 MAPK inhibitor, able to significantly reduce the thrombus size and 
the TF activity in carotid arteries in a mouse model [52]. In a Phase I study, 24 
healthy subjects were exposed to an intravenous dose of LPS preceded 3 hours 
earlier by administration of BIRB 796 BS (another specific p38 MAPK inhibitor), 
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providing  preliminary observations of inhibition of coagulation, fibrinolysis and 
endothelial cell activation [53]. Two randomized, double-blind, placebo-
controlled clinical trials investigated the safety, tolerability and efficacy of 
studies of VX-702, another p38 MAPK inhibitor, in active, moderate-to-severe 
RA patients [54]. Inhibition of NF-kB or p38 MAPK pathway might represent a 
new targeted treatment approach in autoimmune diseases. However, its role in 
APS treatment needs further investigation. 
Complement inhibition. The potential role of complement in the pathogenesis of 
APS is currently receiving a great deal of attention.  There is increasing 
evidence linking the coagulation and complement cascades, including the 
findings that human C5 incubated with thrombin generated C5a, and that C5a 
can trigger the expression of TF [55, 56].  Girardi et al found that C5a-C5aR 
interaction and neutrophils are important mediators of fetal damage in APS. 
Treatment with heparin, the standard therapy for pregnant patients with aPL, 
was observed to prevent complement activation and protected mice from 
pregnancy complications induced by aPL (reviewed in [57]). Mice deficient in 
complement components C3 and C5 were resistant to enhanced thrombosis 
and endothelial cell activation induced by aPL. In addition, inhibition of C5 
activation by anti-C5 monoclonal antibodies has been proposed to reduce aPL-
mediated prothrombotic status [58]. In a mouse-model of APS, a C5a receptor 
antagonist was observed to induce a reduction on aPL-mediated cellular 
effects, including TF expression [59]. The effective use of eculizumab, a 
humanised monoclonal IgG2/4κ antibody that binds the complement protein C5, 
preventing cleavage into C5a and C5 has been reported in severe cases of 
APS, such as the catastrophic variant of the syndrome [60-62].  These findings 
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emphasize the importance of developing and testing complement inhibition 
therapies in patients with APS. The PROMISSE Study (Predictors of 
pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and 
Systemic lupus Erythematosus) [63] is currently evaluating biomarkers that 
predict pregnancy morbidity and will potentially stimulate interventional trials of 
complement inhibition in patients at risk of aPL antibody-associated clinical 
manifestations [64]. 
Blocking of aPL/β2GPI receptors on target cells. The interaction of aPL with 
several cell surface receptors, including annexin A2 and toll-like receptor 4  
(endothelial and monocytes), lipoprotein receptor-related protein family 
(platelets), and C5a receptor (neutrophils) has been investigated as potential 
targets to prevent aPL-induced thrombosis. Evidence indicates that annexin A2, 
a receptor for tissue plasminogen activator and plasminogen, binds beta2GPI on 
target cells. Interestingly, an anti-A2 monoclonal antibody significantly 
decreased aPL-induced expression of thrombophilic molecules on cultured 
endothelial cells, indicating that blocking A2 might reduce the pathogenic effects 
of aPL in inducing thrombosis [65, 66]. Pierangeli and co-workers investigated 
the role of TIFI, a 20 amino acid synthetic peptide that shares similarity with the 
domain V of β2GPI in APS. They observed the ability of TIFI to reduce aPL-
mediated thrombosis in mice by competing with β2GPI and preventing its 
binding to target cells [67].  Inhibition of aPL binding to the receptor proteins on 
target cells might be important in designing new modalities for the treatment of 
thrombosis in APS focusing on immunomodulatory option. 
Several independent groups have demonstrated that polyclonal IgGs derived 
from the patients with APS bind domain I (DI) of β2GPI [68-70]. Therefore, anti-
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DI antibodies are likely to represent an important subpopulation of pathogenic 
anti-β2GPI antibodies. Theoretically, molecules that inhibit binding of these 
aPLs to native DI may be useful as therapeutic agents in patients with APS. 
This hypothesis has been proposed and preliminary results showed that a 
recombinant D1 molecule, and a recombinant mutant D1 with enhanced aPL 
binding properties, may be used as an inhibitor of aPL binding and thus inhibit 
aPL-induced pathogenicity [71]. 
Intravenous immunoglobulins (IVIG). The use of IVIG in obstetric APS refractory 
to standard treatment has currently failed to be implemented widely due to its 
lack of evidence of efficacy, expense and supply shortages [72]. Studies have 
failed to observe statistically significant improvements in obstetric and neonatal 
outcomes with the use of IVIG in combination with aspirin and low molecular 
weight heparin (LMWH), when compared to aspirin and LMWH only regimens 
[73,74]. Consequently, IVIG is often reserved for patients that are refractory to 
LMWH or when additional indications such as autoimmune thrombocytopenia 
are present.  
More recently, two studies [75,76] showed the efficacy of IVIG in addition to 
conventional therapy, in primary and secondary APS patients, in preventing the 
occurrence of further thromboembolic events. However, further clinical studies 
on a larger group of patients are necessary to fully understand the mechanisms 
of action and the optimal doses of IVIG in thrombotic APS. 
Autologous hematopoietic stem cell transplantation. Autologous hematopoietic 
stem cell transplantation (HSCT) is currently being evaluated as a treatment for 
autoimmune diseases [77]. In 2005, Burt and co-workers suggested that 
autologous HSCT might be performed safely in patients with APS and appeared 
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to be effective therapy for eliminating aPL and preventing thrombotic 
complications in patients with SLE [78]. However, few cases of HSCT in APS 
have been reported [79, 80] and long term follow-up data are required before 
this option could be considered a potential therapeutic approach for the 
syndrome. 
Conclusion 
In the long-term management of APS patients, controlled studies with vitamin k 
antagonist alternatives, such as the new anticoagulant agents (oral direct and 
indirect thrombin inhibitors) are essential. Newer therapeutic agents targeting 
pathways involved in the development of aPL-mediated clinical manifestations 
are under investigation. However, the multifactorial mechanisms underlying 
thrombosis and pregnancy morbidity in APS are still not fully understood and 
this might limit the development of new targeted therapies for APS. Potentially, 
the current 'antithrombotic' approach to APS patients will be replaced in the 
future by an 'immunomodulatory' approach as our understanding of the 
mechanisms of aPL-mediated clinical manifestations improves. 
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Take home message:  
 current therapeutic options for the treatment of the antiphospholipid 
syndrome (APS) remain confined to long-term anticoagulation with 
vitamin K antagonists.  
 Novel therapeutic options potentially available include anti-CD20 
monoclonal antibodies and new-generation anticoagulants (such as 
direct thrombin inhibitor and direct anti-Xa inhibitors), statins and HCQ. 
Strategies aimed at cellular aPL/β2GPI targets including domain 1 of 
anti- β2GPI are promising. 
 The challenge will be to undertake carefully designed prospective multi-
centre trials to produce the level of evidence required to support the 
inclusion of new therapies into clinical practice. 
 
 
 
•• An important study describing independent predictors of thrombosis for aPL-positive 
patients including male sex, LA, and persistently positive aCL. 
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Figure 1. Proposed target approaches for APS. (1) Depletion of B cells by anti CD20 
monoclonal antibodies, to reduce pathogenic aPL; (2) Use of small inhibitory peptides 
modelled on domain V (TIFI) or domain I of 2GPI; (3) blocking of aPL/ 2GPI 
receptors on target cells (annexin A2 and Toll-like receptor 4 on endothelial cell and 
monocytes;  lipoprotein receptor-related protein family on platelets; (4) inhibitors of 
complement components (5) inhibitors of intracellular pathway (p38MAPK and NF-kB), 
including BIRB796 BS, SB203580, VX702; (6) reducing arachidonic acid (AA) 
production inhibiting cytosolic phospholipases A2 (cPLA2)  is one of the proposed 
antithrombotic mechanisms of hydroxychloroquine (7) Tissue factor inhibitors, including  
ACE inhibitors, pentoxifylline, an adenosine uptake inhibitor (dilazep), and ss-
deoxyribonucleic acid derivatives (e.g, defibrotide) and newly developed anti-TF 
monoclonal antibodies; (8) New generation anticoagulants targeting FXa or thrombin. 
 
 
 
 
